BioVeris Inc., Igen, Roche deal

ROCZ completed its acquisition of Igen for $1.3 billion in cash and stock (see BioCentury, July 28, 2003). ROCZ renamed the unit BioVeris. IGEN shareholders will receive $47.25 in cash and one BIOV sh...